


IN THE CLAIMS

Claims 1-21 (canceled)


22. (currently amended) A method of treating a host having a flavivirus or rhabdovirus infection, which method comprises administering to the host effective amounts of:

- (a) an interferon, and
- (b) at least one compound selected from the group consisting of:
 - 5-membered cyclic nucleosides having the formula (I):




wherein —X— is =CH— , $\text{—CH}_2\text{—}$ or —O— , Nu is selected from the group consisting of purines, pyrimidines and five- or six-membered aglycones, R_2 and R_3 are independently selected from the group consisting of H, OH, O-acyl, O-aryl and O-silyl, and R_1 is as defined for R_2 and R_3 or is O-phosphate, and pharmaceutically acceptable metabolites, ~~metabolite derivatives~~ and salts thereof; and


~~mycophenolic acid compounds having the formula (II):~~




wherein R_4 is OR_6 or $N(R_7)$, R_8 in which R_6 , R_7 and R_8 are independently selected from the group consisting of hydrogen and C_1 - C_6 alkyl, and R_5 is selected from the group consisting of hydrogen, phenyl and C_1 - C_6 alkyl unsubstituted or substituted by a five- or six-membered saturated or unsaturated heterocyclic ring, and pharmaceutically acceptable salts thereof;
~~imidazole derivatives represented by formula (III):~~



wherein R_9 is a hydrogen atom or




wherein R_{10} is a hydrogen atom, C_1 - C_6 alkyl, hydroxy(C_1 - C_6 alkyl) or phenyl, R_{11} and R_{13} are independently selected from hydrogen and OR_{12} and R_{12} is a hydrogen atom or a hydroxy protecting group and A is $CONH_2$ or CN , and pharmaceutically acceptable salts thereof;
~~aminoadamantanes having the formula (IV):~~




wherein each of R_{14} , R_{15} , R_{16} and R_{17} is independently selected from the group consisting of H, F and CH_3 and X is $N(R_{18})_2$, $CH_2CH_2N(R_{18})_2$ or $C(R_{19})_2N(R_{18})_2$ wherein each R_{18} and R_{19} is H, (C_1-C_6) alkyl, (C_6-C_{10}) aryl and (C_7-C_{18}) aralkyl; and

2,4-diaminopyrimidines having the formula (V):



wherein R_{20} is phenyl substituted by one or more substituents selected from the group consisting of benzyl, NO_2 , (C_1-C_6) alkylamino and halogen and R_{21} is H or C_1-C_6 alkyl; or R_{20} and R_{21} form, together with the 2,4-diaminopyrimidine ring to which they are attached, a quinazoline derivative of formula (V'):



wherein Z is $-\text{CH}_2\text{NR}_{23}-$ or $-\text{NR}_{23}\text{CH}_2-$; R_{22} , R_{23} and R_{24} are each, independently, H or $\text{C}_1\text{-C}_6$ alkyl; and n is 1 or 2, and pharmaceutically acceptable salts thereof.

23. (previously presented) A method according to claim 22, wherein the flavivirus is selected from yellow fever virus, kunjin virus, dengue virus, hepatitis C virus, St. Louis encephalitis virus, Japanese encephalitis virus, Murray valley encephalitis virus and tick-borne encephalitis virus.

24. (previously presented) A method according to claim 22, wherein the rhabdovirus is selected from vesicular stomatitis virus (VSV) and rabies virus.

25. (previously presented) A method according to claim 22, wherein the interferon (a) is a human interferon.

26. (previously presented) A method according to claim 22, wherein the interferon is selected from interferon $\alpha 2$, interferon $\alpha 8$ and interferon β .

27. (previously presented) A method according to claim 26, wherein the interferon is human interferon $\alpha 8$ having a specific activity of from 0.6×10^9 to 1.5×10^9 IU per mg protein.

28. (currently amended) A method according to claim 26, wherein the interferon is human interferon β having a specific activity of from 4×10^8 to 8×10^8 IU per mg protein.

29. (previously presented) A method according to claim 22, wherein the compound (b) is at least one compound selected from the group consisting of cyclopentenyl cytosine, mycophenolic acid, 5-ethynyl-1- β -D-ribofuranosylimidazole-4-carboxamide, amantadine hydrochloride, 3-deazaneplanocin, neplanocin A, 3-deazauridine, 6-azauridine,

aristeromycin, pyrazofurin, tiazafurin, selenofurin, NSC 382046, NSC 7364, NSC 302325, NSC 184692D and NSC 382034.

30. (withdrawn) Products containing an interferon and at least one compound (b) as defined in claim 22 as a combined preparation for simultaneous, separate or sequential use in treating a flavivirus or rhabdovirus infection.


Claims 31-37 (canceled)

38. (previously presented) A method of treating a host having a flavivirus or rhabdovirus infection, which method comprises the step of administering to the host, in respective amounts which produce a synergistic ant Flaviviral or antirhabdoviral effect, an interferon and at least one compound (b) as defined in claim 22.

39. (withdrawn) An agent for use in the treatment of a flavivirus or rhabdovirus infection, which comprises an interferon and at least one compound (b) as defined in claim 22.


Kindly enter the following new claims.

40. (new) A method according to claim 22, wherein Nu is selected from the group consisting of:



wherein R_{23} is Cl or NH_2 and R_{26} is H, CH_3 , CF_3 , F, CL, Br or I.

41. (new) A method of treating the host having a flavivirus or rhabdovirus infection, which method comprises the step of administering to the host, in respective amounts which produce a synergistic antflaviviral or synergistic antirhabdoviral effect, an interferon and at least one aminoadamantane of formula IV:



wherein each of R₁₄, R₁₆ and R₁₇ independently selected from the group consisting of H, F and CH₃ and X is N(R₁₈)₂, CH₂CH₂N(R₁₈)₂ or C(R₁₉)₂N(R₁₈)₂ wherein each R₁₈ and R₁₉ is H, (C₁-C₆) alkyl, (C₆-C₁₀) aryl and (C₇-C₁₈) aralkyl.